Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Clinical evidence

ABX464-108

41 evidence topics · 6 sources

Objective
Location and study date
Study design
Design details in the ClinicalTrials.gov record
FieldQuoted record
Allocation“N/A”
Interventional model“Single Group Assignment”
Interventional model description“Open Label Follow-up Study”
Masking“None (Open Label)”
Phase“Phase 2”
Enrollment (estimated)“203”
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Participants analyzed in the congress presentation
AnalysisQuoted record
Safety, all participants“n = 130”
Week 144 completers“n=104”
Week 144 completers naive to advanced therapy inadequate response“57”
Week 144 completers with prior advanced therapy inadequate response“47”
Description of analysis sets
Results
Participant disposition
Participants at each timepoint in the program schema
TimepointQuoted record
Week 48“n= 114”
Week 96“n=107”
Completed week 144“n=104”
Baseline characteristics
Characteristics at the start of the 25 mg dose among week 144 completers
CharacteristicWeek 144 completers (n=104)
Age, years, mean (SD)“45.4 (12.74)”
Male, n (%)“65 (62.5)”
UC duration, years, mean (SD)“11.2 (7.02)”
Modified Mayo score 0 to 4, n (%)“104 (100)”
C-reactive protein, mg/L, median“2.2”
Fecal calprotectin, µg/g, median“57.0”
Concomitant corticosteroids, n (%)“6 (5.8)”
Concomitant 5-ASA, n (%)“79 (76.0)”
Prior refractoriness to biologics, n (%)“49 (47.1)”
Primary non-response, n (%)“19 (38.8)”
Loss of response, n (%)“30 (61.2)”
Efficacy results
Efficacy endpoints among week 144 completers
Endpoint (n=104)BaselineWeek 48Week 96Week 144
Clinical remission“91%”“85%”“85%”“85%”
Symptomatic remission“92%”“90%”“88%”“90%”
Endoscopic improvement“99%”“92%”“93%”“92%”
Endoscopic remission“66%”“66%”“72%”“72%”
Efficacy endpoints among week 144 completers by prior advanced therapy inadequate response
Endpoint and subgroupBaselineWeek 48Week 96Week 144
Clinical remission, AT-IR naive (N=57)“97%”“91%”“88%”“90%”
Clinical remission, prior AT-IR (N=47)“85%”“77%”“80%”“79%”
Symptomatic remission, AT-IR naive (N=57)“97%”“97%”“91%”“95%”
Symptomatic remission, prior AT-IR (N=47)“87%”“83%”“85%”“85%”
Endoscopic improvement, AT-IR naive (N=57)“100%”“93%”“95%”“95%”
Endoscopic improvement, prior AT-IR (N=47)“98%”“92%”“91%”“89%”
Endoscopic remission, AT-IR naive (N=57)“84%”“77%”“84%”“81%”
Endoscopic remission, prior AT-IR (N=47)“45%”“53%”“57%”“62%”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Treatment-emergent adverse events in all 130 participants
EventN (%) [IR/100 PY]
Any TEAE“96 (73.8) [87.9]”
TEAE leading to discontinuation“9 (6.9) [4.25]”
Serious TEAE“8 (6.2) [3.86]”
Ulcerative colitis“15 (11.5) [7.3]”
Nasopharyngitis“11 (8.5) [5.4]”
Upper respiratory tract infection“10 (7.7) [4.9]”
COVID-19“11 (8.5) [5.4]”
Hypertension“7 (5.4) [3.4]”
Diarrhea“5 (3.8) [2.4]”
Arthralgia“5 (3.8) [2.4]”
Gastroenteritis“4 (3.1) [1.9]”
Non-melanoma skin cancer“1 (0.8) [0.5]”
Study limitations
Summary

ABX464-108 (Study 108) is an ongoing single-group, open-label extension without a control group, in which participants who completed the phase 2a (ABX464-102) or phase 2b (ABX464-104) open-label maintenance studies on obefazimod 50 mg, and who had a Mayo endoscopic subscore of 0 or 1 and a rectal bleeding subscore of 0, received obefazimod 25 mg once daily. Entry selected participants already in endoscopic improvement after 2 to 4 years of treatment: of 174 who completed the earlier studies, 138 were eligible and 130 were treated, and 89% (116/130) were in clinical remission at study baseline. The study has no randomized comparison of 25 mg with continued 50 mg. Results come from an interim analysis presented at a congress and in a press release (January 5, 2026 cutoff; February 13, 2026 data transfer); no peer-reviewed report or registry results exist, and primary completion is estimated for March 2028. Clinical remission by non-responder imputation was 73%, 69%, and 68% at weeks 48, 96, and 144. The baseline characteristics and the subgroup analyses by prior advanced therapy inadequate response were reported only for the 104 participants who completed week 144, among whom clinical remission was 84% to 85% in the as-observed analysis. Sources state the treatment period differently: a maximum of 54 months in the registry summary, 78 months in the registry outcome time frame and the poster, and up to five additional years in the press release. The number completing week 48 is 113 in the poster and 114 on a presentation slide, and the number completing the phase 2a extension is 10 in the poster and 11 in the posted ABX464-102 results. The safety table excludes laboratory findings. No health-related quality of life results were located.